Trinity Biotech plc (NASDAQ: TRIB) (ISE: TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has written to the United States Food and Drug Administration (FDA) requesting a meeting to discuss the conditions under which the FDA might grant marketing clearance for Over The Counter (OTC) sale of the company’s UniGold HIV test. In addition Trinity will present at a meeting of the Blood Products Advisory Committee (BPAC) of the FDA in Washington tomorrow Friday 10th March 2006 and will present its position on home testing for HIV.
